DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Building BlocksBuilding Blocks
  4. /Heterocyclic ScaffoldsHeterocyclic Scaffolds
  5. /TetrahydropyransTetrahydropyrans
  6. /Methyl O-2,3,4-tri-O-methyl-6-O-sulfo-alpha-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-beta-D-glucopyranuronosyl-(1->4)-O-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-alpha-L-idopyranuronosyl-(1->4)-alpha-D-glucopyranoside 2,3,6-tris(hydrogen sulfate)CAS 162610-17-5
Chemical structure of CAS 162610-17-5

Methyl O-2,3,4-tri-O-methyl-6-O-sulfo-alpha-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-beta-D-glucopyranuronosyl-(1->4)-O-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-alpha-L-idopyranuronosyl-(1->4)-alpha-D-glucopyranoside 2,3,6-tris(hydrogen sulfate)

CAS No.162610-17-5
MDL No.N/A
MFC38H64O49S7
MW1529.40
InChI KeyAJBMORBNKXNZSF-COSHMZDQSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.162610-17-5
Product NameMethyl O-2,3,4-tri-O-methyl-6-O-sulfo-alpha-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-beta-D-glucopyranuronosyl-(1->4)-O-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-alpha-L-idopyranuronosyl-(1->4)-alpha-D-glucopyranoside 2,3,6-tris(hydrogen sulfate)

Biological Targets

F10

Associated Conditions

deep vein thrombosis·pulmonary embolism·atrial fibrillation
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.

British journal of haematology • Vol. 124, Issue 5 • 2004
PMID: 14871253DOI: 10.1111/j.1365-2141.2003.04811.x

Idraparinux and liver enzymes: observations from the PERSIST trial.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis • Vol. 14, Issue 1 • 2003
PMID: 12544730DOI: 10.1097/01.mbc.0000046199.72384.ef

[New and future antithrombotic agents in thrombo-embolic venous disease].

La Revue du praticien • Vol. 53, Issue 1 • 2003
PMID: 12673926

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

Thrombosis research • Vol. 109, Issue 1 • 2003
PMID: 12679126DOI: 10.1016/s0049-3848(03)00030-6

Documentation

Similar Products

  • Pentosan Polysulfate

    CAS No.37300-21-3

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact